Vincerx Pharma announces termination of reverse merger term sheet

Vincerx Pharma (VINC) announced that the previously signed binding Term Sheet between Vincerx, Oqory, and Vivasor for a reverse merger transaction has been terminated. As a result, the board of directors will reassess the company’s strategic alternatives, including out-licensing, merger and acquisition opportunities, the sale of assets and technologies, and winding down operations, among other potential transactions. As of February 26, the company had approximately $3.9M in cash. The company’s cash runway is expected to extend through late Q2 2025.